Is the Fun Over for Orexigen (OREX)? (VVUS) (ARNA)
Tweet
Share
E-mailGet Alerts OREX Hot Sheet
Join SI Premium – FREE
Shares of Orexigen Therapeutics (Nasdaq: OREX) ran up into the approval VIVUS (Nasdaq: VVUS) Qsymia and Arena's (Nasdaq: ARNA) Belviq, which happened within weeks of each other. Both are new weight-management drugs, the first approved in the U.S. in the last 13 years.
Now, Orexigen holders will still need to wait about two years before its proposed obesity pill, Contrave, is approved.
So, with Orexigen starting May at around $3.50, will investors and traders be anticipating a 50 percent drop in the shares? Or will Arena and VIVUS be enough to sustain hope for the next 18 to 42 months?
Orexigen is trading 3.2 percent lower at the start Thursday, looking at a third day of losses.
Now, Orexigen holders will still need to wait about two years before its proposed obesity pill, Contrave, is approved.
So, with Orexigen starting May at around $3.50, will investors and traders be anticipating a 50 percent drop in the shares? Or will Arena and VIVUS be enough to sustain hope for the next 18 to 42 months?
Orexigen is trading 3.2 percent lower at the start Thursday, looking at a third day of losses.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Equifax (EFX) shares tumble on weak Q1 revenue, guidance miss
- Aluminum and steel stocks rise as Biden calls for higher tariffs
- Pfizer (PFE) drops to 11-year lows
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
